Skip to main content

Table 4 Percentual changes (expressed as median and interquartile interval) in parameters of heart rate variability analyzed in the time- and frequency-domains or using non-linear analysis during the tilt test in patients belonging to each of the studied groups: HIV seronegative controls (n = 35) and HIV seropositive patients of Group 1 (treated with 3TC, TDF, EFV, n = 44) and Group 2 (treated with 3TC + AZT; 3TC + TDF + LPV/r, n = 42) with suppressed viremia

From: Linear and non-linear analysis of heart rate variability in HIV-positive patients on two different antiretroviral therapy regimens

 

HIV seronegative controls

HIV seropositive

p value

Group 1

(3TC, TDF, EFV)

Group 2

(3TC + AZT; 3TC + TDF + LPV/r)

Number

35

44

42

 

Time-domain analysis

    

 Mean RRi (%)

 − 11.39 (12.51)

 − 14.01 (10.00)

 − 10.95 (8.68)

NS (0.416)

 STD RR (%)

 − 9.43 (45.59)

 + 5.08 (37.29)

 + 6.29 (66.18)

NS (0.314)

 pNN50 (%)

 − 45.47 (92.35)

 − 66.97 (41.50)

 − 65.04 (116.90)

NS (0.321)

 RMSSD (%)

 − 5.60 (44.92)

 − 35.96 (31.52)

 − 29.16 (59.77)

NS (0.078)

Frequency-domain analysis

    

 LF freq. (%)

 − 10.10 (26.70)

 + 3.75 (41.89)

0.00 (17.73)

NS (0.279)

 LF power (%)

 + 17.01 (189.21)

 − 3.38 (103.13)

 − 6.14 (135.12)

NS (0.338)

 LF (n.u.) (%)

 + 28.35 (36.48)

 + 23.45 (32.32)

 + 11.93 (35.23)

NS (0.432)

 HF freq. (%)

0.00 (31.22)

0.00 (16.91)

 − 3.54 (41.69)

NS (0.697)

 HF power (%)

 − 60.47 (116.99)

 − 62.43 (48.59)

 − 52.29 (125.62)

NS (0.886)

 HF (n.u.) (%)

 − 52.77 (78.63)

 − 43.23 (52.22)

 − 33.23 (62.95)

NS (0.120)

 LF/HF ratio (%)

 + 155.00 (534.86)

 + 119.78 (306.38)

 + 81.29 (251.76)

NS (0.408)

Non-linear analysis

    

 Poincaré plot

    

  SD1 (%)

 − 7.38 (41.62)

 − 34.52 (30.59)

 − 27.85 (60.14)

NS (0.364)

  SD2 (%)

 − 12.37 (33.74)

 + 10.34 (58.18)

 + 14.02 (63.19)

NS (0.051)

 Recurrence plot

    

  Mean line length (%)

 + 8.12 (55.04)

 + 33.04 (75.52)

 + 25.98 (80.96)

NS (0.074)

  Max line length (%)

 + 1.16 (116.41)

 + 24.62 (111.13)

 − 1.67 (122.92)

NS (0.868)

  Recurrence rate (%)

 + 2.99 (41.08)

 + 26.21 (52.27)

 + 21.63 (45.34)

NS (0.089)

  Determinism rate (%)

 + 0.01 (2.09)

 + 0.58 (0.84)

 + 0.54 (1.65)

NS (0.085)

 Detrended fluctuation analysis

    

  α1 (%)

 + 3.52 (40.47)

 + 25.40 (30.84)

 + 26.19 (34.42)

NS (0.085)

  α2 (%)

 + 4.17 (36.00)

 + 6.02 (38.05)

 + 10.07 (53.89)

NS (0.620)

 Complexity

    

  Approximate entropy (%)

 − 8.13 (32.82)

 − 26.73 (25.43)

 − 21.14 (19.03)

NS (0.094)

  Sample entropy (%)

 − 3.45 (47.53)

 − 35.95 (40.50)

 − 24.30 (41.60)

NS (0.079)

  Correlation dimension (%)

 − 30.77 (84.03)

 − 21.96 (68.76)

 − 2.85 (166.96)

NS (0.730)

  1. Data are expressed as median (percentile 25, percentile 75). p = significance level from Kruskall-Wallis ANOVA; NS = non significant; LF = low frequency; HF = high frequency; LH/HF = ratio between low and high frequency bands; n.u. = normalized units. 3TC = lamivudine, TDF = tenofovir, EFV: efavirenz, AZT = zidovudine, LPV = lopinavir, r = ritonavir
  2. *p < 0.05 versus control group